Sabin is working in Latin America to bring together experts to discuss some of the key questions of dengue burden and vaccine introduction. Sabin is coordinating a two day regional workshop to convene key health and government officials from the region, as well as officials from the Pan American Health Organization (PAHO) and representatives from multilateral agencies and other stake holders, to discuss how to measure efficacy of a future dengue vaccine and to develop a proposed set of guidelines on methodologies to be used.
Dengue, also known as breakbone fever, is a painful and sometimes fatal viral disease characterized by headache, skin rash and debilitating muscle and joint pains. In some cases, it can lead to circulatory failure, shock, coma and death. The incidence of dengue has grown dramatically around the world in recent decades, and the latest figures estimate that there are 96 million symptomatic cases of dengue around the world each year.
Sabin works with partners around the world, including the World Health Organization (WHO), the Pan American Health Organization (PAHO), Fundação Oswaldo Cruz (FIOCRUZ) and the Bill & Melinda Gates Foundation, to convene symposiums that have brought together more than 2,400 of the world’s global health stakeholders to work on advancing vaccination as a cost-effective weapon in public health.
Sabin is dedicated to reducing the burden and impact of infectious diseases through the use of new and underutilized vaccines.
July 10, 2013
July 9, 2013
July 12, 2013